The final issue in our health series brings in a global perspective. Four of our authors take a look at the EU approach to pharm.; in particular, at the Italian Pfizer case, the Boehringer decision, and court developments since Astra-Zeneca: Is there a pattern? Back in the U.S. we wonder if K-Dur will force the Supreme Court to look at reverse payments. And for a series wrap-up we ask, “Should policy focus on reducing health care costs?” Finally, taking a breather from health care, we present some interesting policy thoughts from China and Russia. We hope you’re enjoying the Olympics!

The Muddled EU Approach to Pharm

Daniela Ampollini, Jul 27, 2012

Looking for Sense in the Italian Antitrust Authority Decision in the Pfizer Xalatan Case

The IAA could find for the existence of the abuse only by misconstruing the very essence of patent law. Daniela Ampollini (Trevisan & Cuonzo)

Stefano Grassani, Jul 27, 2012

From Astra-Zeneca to Pfizer: When Protection of Originators Patents Ceases to be a “Right and Becomes an Abuse of Dominance

National agencies do not refrain from dealing with sensitive and critical matters such as the interplay between IP and antitrust law which one would assume the EU Commission would be primarily addressing. Stefano Grassani (Pavia e Ansaldo)

Sean-Paul Brankin, Jul 27, 2012

European Commission Enforcement in the Pharmaceutical Sector: Less Than Expected? The Boehringer Case Closure Suggests As Much

The implication a


Please sign in or join us
to access premium content!